Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales...
Covered in this story
Call it yourself
No calls on $NINE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Nine Energy Service →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.